On CNBC's "Fast Money," Link said that Phase 1 data of NewLink's vaccine is expected in December 2014.

The drug is currently being tested on 500 human volunteers in the United States, Britain, Germany, Switzerland, Mali, Gabon and Kenya. That Phase 1 data will determine the efficacy of the drug based on the human's antibody response to the vaccine.

"That data will be used to make a choice to then launch the larger scale trial (in West Africa) in a phased version in January of next year but it's a little hard to nail that date down today," said Link.